EUCTR2006-000635-94-GB进行中（未招募）1 期
A Phase II, randomized, double-blind, parallel group study to examine bone quality and bone mineral density changes following treatment with SB-462795 (40mg, 80mg, 120mg or 160mg), alendronate or placebo in postmenopausal women with osteoporosis.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1.Subjects who have signed informed consent.
- •2.Ambulatory postmenopausal women <80 years of age at screening. (Postmenopausal is defined as 3 years of spontaneous amenorrhea or 1 year post surgical bilateral oophorectomy at baseline. In those cases where bilateral oophorectomy status is uncertain, follicle stimulating hormone [FSH] levels >40 mIU/ml can be used to confirm surgical postmenopausal status).
- •3.Subjects who, in the opinion of the investigator, are willing and able to comply with the protocol requirements.
- •4.BMD T-Score =-2.0 at the femoral neck, total hip, or lumbar spine at the Screening visit. All subjects must have BMD T-scores > -3.5 at all three sites at the Screening visit.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Any previous osteoporotic fracture or previously documented Grade 2 or worse prevalent vertebral fracture or one or more Grade 2 or 3 vertebral fracture(s) identified by baseline vertebral fracture assessment (VFA) of the spine.
- •2.Less than three vertebra in the range of L1 to L4 that are suitable for BMD measurement by DXA.
- •3.Significant spine deformity which would preclude VFA assessment.
- •4.History of hip surgery resulting in a metal implant which would cause artifact on a CT scan.
- •5.Subjects with a history of, or ongoing diffuse collagen related diseases or autoimmune related diseases
- •6.Subjects with localized morphea or Raynaud’s phenomenon.
- •7.A marked baseline prolongation of QT/QTc interval
- •8.A history of additional risk factors for Torsades de Pointes
- •9.Any clinically relevant biological abnormality found at screening (other than those related to the disease under investigation) which, in the opinion of the investigator, is clinically significant and would preclude safe participation in this study
- •10.Malignant disease diagnosed within the previous 5 years (except resected basal cell cancer).
- •11.History of major upper gastrointestinal disease defined by:
- •Significant upper gastrointestinal bleeding within the last year requiring hospitalization or transfusion;
- •Recurrent peptic ulcer disease documented by radiographic or endoscopic means;
- •Dyspepsia or gastroesophageal reflux that is uncontrolled by medication;
- •Abnormalities of the esophagus that delay esophageal emptying, such as stricture, achalasia, or dysmotility;
- •Active gastric/duodenal ulcers;
- •Subjects are not excluded because of previous or active gastrointestinal disease , except as outlined above.
- •12.Malabsorption syndrome
- •13.Inability to swallow a tablet whole.
- •14.Contraindications to therapy with calcium, vitamin D or alendronate.
- •15.Administration of any investigational drug within 90 days preceding the first dose of the study drug.
- •16.History or current evidence of drug or alcohol abuse within the previous 12 months.
- •17.Other than osteoporosis, history or concurrent diseases affecting bone metabolism. Subjects receiving thyroid hormone replacement therapy must be on a stable dosing regimen for at least 3 months prior to screening.
- •18.Previous treatment with an oral bisphosphonate as follows:
- •Any treatment within the last six months,
- •=one month cumulative treatment within the last 12 months,
- •=three months cumulative treatment within the past two years, or
- •=two years cumulative treatment within the past five years
- •19.Any previous treatment with intravenous bisphosphonate.
- •20.Treatment with strontium ranelate within the past year.
- •21.Treatment with fluoride for osteoporosis (dose greater than 10mg/day) within the last 12 months, or past treatment for more than a total of two years.
- •22.Treatment with PTH or similar anabolic agent for osteoporosis within the last two years.
- •23.Treatment with other drugs affecting bone metabolism within the last six months prior to screening:
- •chronic systemic corticosteroid treatment (oral, parenteral, intra-articular, or long-term, high-dose inhaled) except for topical treatment at a frequency of up to twice per week
- •hormones [e.g., estrogens/natural estrogen preparations(except for topical treatment at a frequency of up to twice per week), 19-norprogestins, SERM such as raloxifene, anabolic steroids/androgens such as dehydroepiandrosterone (DHEA) or its sulfate
研究者
相似试验
进行中（未招募）
1 期
Dose-finding study of moxidectin for the treatment of scabiesScabies (infection with Sarcoptes scabiei)MedDRA version: 20.1Level: LLTClassification code 10039511Term: ScabiesSystem Organ Class: 100000004862EUCTR2019-001775-37-FRMedicines Development Limited (trading as Medicines Development for Global Health)18
进行中（未招募）
1 期
Dose-finding study of moxidectin for the treatment of scabiesEUCTR2019-001775-37-ATMedicines Development for Global Health Limited36
进行中（未招募）
不适用
A phase II, randomized, double-blind, parallel groups study to assess the efficacy and safety of Nimodipine 20 mg + Betahistine 16 mg versus Placebo + Betahistine 16 mg in the treatment of vertigoVertigoMedDRA version: 16.1Level: PTClassification code 10047340Term: VertigoSystem Organ Class: 10013993 - Ear and labyrinth disordersEUCTR2013-005122-33-ITMDM S.p.A.
进行中（未招募）
1 期
A phase II, double-blind, randomized, parallel-group, placebocontrolled multi-center study to investigate the effect of the adenosine A1 receptor antagonist PBF-680 on forced expiratory volume in 1 second (FEV1) in patients with mild-to-moderate persistent atopic asthmapatients with mild-to-moderate persistent atopic asthmaMedDRA version: 20.0Level: LLTClassification code 10003638Term: Atopic asthmaSystem Organ Class: 100000004855EUCTR2017-003663-35-ESPalobiofarma S.78
进行中（未招募）
不适用
A phase II, randomized, double-blind, parallel-group, placebo-controlled, 12-week treatment, adaptive proof-of-principle study of twice daily oral dosing of a novel PDE4 inhibitor (ASP9831) in subjects with non-alcoholic steatohepatitis (NASH) - ASTERon-alcoholic Steatohepatitis (NASH)MedDRA version: 9.1Level: LLTClassification code 10053219Term: Non-alcoholic steatohepatitisEUCTR2007-002114-19-GBAstellas Pharma Europe B.V.105